Manufacturer Supply 99% Purity Antidepressant Raw Material Brexpiprazole Powder CAS 913611-97-9 Brexpiprazole
Meister Supply is an enterprise committed to the development, production. sales and transportaion of chemical products. The company has a long-term cooperative relationship with Bejing Research institute of Chemical Industry and its affliated universities at home and abroad. It is a research and development enterprise of new chemicl materials for the global chemical market demand. "Continuous innovation, quality assurance" is our purpose. It integrates the research and development, industrialization and marketization of innovative chemical new materials. The company has strong technical strength, advanced equipment, strict guality management system and quality afer-sales service. Over the years, our products have been widely sold to many countries and regions, and we have established stable cooperative relations with trades and end users all over the world. Relying on a strong logistics system, we have established our own overseas warehouses in the United States, Mexico, Canada and the Netherlands. Hot local products can be shipped from overseas warehouses. Well received by local customers. It has become a powerful bridge between suppliers, traders and end users. We look forward to more
Product Description
Brexpiprazole Chemical Properties |
Melting point |
179 - 181oC |
Boiling point |
675.2±55.0 °C(Predicted) |
density |
1.245±0.06 g/cm3(Predicted) |
storage temp. |
Refrigerator |
form |
Solid |
pka |
11.22±0.70(Predicted) |
color |
White to Off-White |
Function
The drug was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. It has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Application
The drug was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. It has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Detailed Photos
Related product
Shipping&Payment